Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease
Background Standardized manual region of interest (ROI) sampling strategies for hepatic
MRI steatosis and iron quantification are time consuming, with variable results. Purpose To …
MRI steatosis and iron quantification are time consuming, with variable results. Purpose To …
Early and accurate diagnosis of steatotic liver by artificial intelligence (AI)-supported ultrasonography
Objectives Steatotic liver disease is the most frequent chronic liver disease worldwide.
Ultrasonography (US) is commonly employed for the assessment and diagnosis. Few …
Ultrasonography (US) is commonly employed for the assessment and diagnosis. Few …
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol
AM Fischer, N Lechea, HO Coxson - Seminars in Liver Disease, 2024 - thieme-connect.com
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent condition
with a broad spectrum defined by liver biopsy. This gold standard method evaluates three …
with a broad spectrum defined by liver biopsy. This gold standard method evaluates three …
Point‐of‐care magnetic resonance technology to measure liver fat: phantom and first‐in‐human pilot study
M Barahman, E Grunvald, PJ Prado… - Magnetic resonance …, 2022 - Wiley Online Library
Purpose To assess feasibility and accuracy of point‐of‐care (POC) NMR‐proton density fat
fraction (PDFF) in phantoms and in a human pilot study in a POC setting. Methods POC …
fraction (PDFF) in phantoms and in a human pilot study in a POC setting. Methods POC …
Exploring factors associated with non-alcoholic fatty liver disease using longitudinal MRI
F Horn, T Ittermann, ML Kromrey, D Seppelt… - BMC …, 2024 - Springer
Background To identify factors associated with non-alcoholic fatty liver disease over a 5-year
period. Methods Three hundred seven participants, including 165 women, with a mean age …
period. Methods Three hundred seven participants, including 165 women, with a mean age …
Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent …
F Castagnoli, R Donners, N Tunariu… - The British Journal of …, 2023 - academic.oup.com
Objectives To compare relative fat fraction (rFF) of active bone lesions from breast, prostate
and myeloma malignancies and normal bone marrow; to assess its inter-reader agreement …
and myeloma malignancies and normal bone marrow; to assess its inter-reader agreement …
Repeatability and accuracy of various region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification
CW Hong, JY Cui, D Batakis, Y Xu, T Wolfson… - Abdominal …, 2021 - Springer
Purpose To evaluate repeatability of ROI-sampling strategies for quantifying hepatic proton
density fat fraction (PDFF) and to assess error relative to the 9-ROI PDFF. Methods This was …
density fat fraction (PDFF) and to assess error relative to the 9-ROI PDFF. Methods This was …
Comparison of reader agreement, correlation with liver biopsy, and time-burden sampling strategies for liver proton density fat fraction measured using magnetic …
D Cao, M Li, Y Liu, H Jin, D Yang, H Xu, H Lv, JI Liu… - BMC Medical …, 2022 - Springer
Background The magnetic resonance imaging (MRI)-based proton density fat fraction
(PDFF) has become popular for quantifying liver fat content. However, the variability of the …
(PDFF) has become popular for quantifying liver fat content. However, the variability of the …
非酒精性脂肪性肝炎新药临床试验的难度与挑战.
黄樱硕， 董瑞华， 尤红 - Journal of Clinical Hepatology …, 2021 - search.ebscohost.com
近年来非酒精性脂肪性肝炎(nAsH) 的发病率不断增长, 且临床上缺乏有效的治疗药物. 从nAsH
的异质性(如体质量, 性别, 年龄和代谢因素), 混杂因素的影响, 量化指标的诊断一致性等方面分析 …
的异质性(如体质量, 性别, 年龄和代谢因素), 混杂因素的影响, 量化指标的诊断一致性等方面分析 …
非酒精性脂肪性肝炎新药临床试验方案的系统评价.
黄樱硕， 魏巍， 佟小非， 孙亚朦… - Journal of Clinical …, 2022 - search.ebscohost.com
黄樱硕a,魏巍b,佟小非c,d,e,孙亚朦c,d,e,张健雄a,董瑞华a,贾继东c,d,e,尤红c, Page 1 $%!" 非酒精
性脂肪性肝炎新药临床试验方案的系统评价 黄樱硕a,魏巍b,佟小非c,d,e,孙亚朦c,d,e,张健雄 …
性脂肪性肝炎新药临床试验方案的系统评价 黄樱硕a,魏巍b,佟小非c,d,e,孙亚朦c,d,e,张健雄 …